Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MediWound Ltd. (MDWD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.3900+0.0400 (+2.96%)
At close: 04:00PM EDT
Advertisement

MediWound Ltd.

42 Hayarkon Street
Yavne 8122745
Israel
972 7 797 14100
https://www.mediwound.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Prof. Lior Rosenberg M.D.Co-Founder & Medical Director398kN/A1946
Mr. Boaz Gur-Lavie CPA, M.B.A.Chief Financial Officer309kN/A1974
Mr. Yaron Meyer Adv.Exec. VP, Gen. Counsel & Corp. Sec.240kN/A1979
Dr. Ety KlingerChief R&D Officer344kN/A1962
Mr. Ofer Gonen B.Sc.Chief Exec. OfficerN/AN/A1973
Mr. Tzvi Palash B.Sc., M.Sc.Chief Operating OfficerN/AN/A1957
Mr. Stephen T. Wills CPA, CPA, MSTExec. DirectorN/AN/A1957
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Corporate Governance

MediWound Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement